Which has higher valuation and earnings, PYPD or ELMD?

Electromed has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.91 N/A Electromed $71.75M 4.45 $5.15M $1.17 32.93

Is PYPD or ELMD more profitable?

Electromed has a net margin of 11.34% compared to PolyPid's net margin of 0.00%. Electromed's return on equity of 15.71% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Electromed 11.34% 15.71% 13.37%

Which has preferable valuation & earnings, PYPD or CARL?

Carlsmed has higher revenue and earnings than PolyPid. Carlsmed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.91 N/A Carlsmed $50.51M 5.75 -$29.63M -$2.51 N/A

Is PYPD or CARL more profitable?

PolyPid has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% Carlsmed -57.76% -60.74% -29.84%

Is SGHT or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -46.83% -52.34% -28.49% PolyPid N/A -241.96% -126.91%

PolyPid (PYPD) Competitors

$4.99 -0.14 (-2.73%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$5.00 +0.01 (+0.20%)

As of 06/23/2026 06:33 PM Eastern

Compare

PYPD vs. ELMD, CARL, SGHT, TLSI, and TMCI

Should you buy PolyPid stock or one of its competitors? MarketBeat compares PolyPid with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PolyPid include Electromed (ELMD), Carlsmed (CARL), Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry.

How does PolyPid compare to Electromed?

PolyPid (NASDAQ:PYPD) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

PolyPid currently has a consensus price target of $11.67, suggesting a potential upside of 133.80%. Electromed has a consensus price target of $37.50, suggesting a potential downside of 2.67%. Given PolyPid's higher possible upside, analysts plainly believe PolyPid is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

In the previous week, Electromed's average media sentiment score of 1.00 beat PolyPid's score of 0.00 indicating that Electromed is being referred to more favorably in the news media.

Company	Overall Sentiment
PolyPid	Neutral
Electromed	Positive

PolyPid has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Electromed has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Comparatively, 10.5% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Electromed has a net margin of 11.34% compared to PolyPid's net margin of 0.00%. Electromed's return on equity of 15.71% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Electromed	11.34%	15.71%	13.37%

Electromed has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Electromed	$71.75M	4.45	$5.15M	$1.17	32.93

Summary

Electromed beats PolyPid on 11 of the 15 factors compared between the two stocks.

How does PolyPid compare to Carlsmed?

PolyPid (NASDAQ:PYPD) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

PolyPid has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Carlsmed	-57.76%	-60.74%	-29.84%

PolyPid presently has a consensus target price of $11.67, suggesting a potential upside of 133.80%. Carlsmed has a consensus target price of $19.33, suggesting a potential upside of 80.85%. Given PolyPid's stronger consensus rating and higher probable upside, analysts plainly believe PolyPid is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, PolyPid's average media sentiment score of 0.00 equaled Carlsmed'saverage media sentiment score.

Company	Overall Sentiment
PolyPid	Neutral
Carlsmed	Neutral

Carlsmed has higher revenue and earnings than PolyPid. Carlsmed is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Carlsmed	$50.51M	5.75	-$29.63M	-$2.51	N/A

Summary

PolyPid beats Carlsmed on 8 of the 12 factors compared between the two stocks.

How does PolyPid compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

PolyPid has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
PolyPid	N/A	-241.96%	-126.91%

PolyPid has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.81	-$38.43M	-$0.71	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

In the previous week, Sight Sciences had 1 more articles in the media than PolyPid. MarketBeat recorded 1 mentions for Sight Sciences and 0 mentions for PolyPid. Sight Sciences' average media sentiment score of 0.59 beat PolyPid's score of 0.00 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sight Sciences	Positive
PolyPid	Neutral

Sight Sciences has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Sight Sciences presently has a consensus price target of $8.14, suggesting a potential upside of 50.53%. PolyPid has a consensus price target of $11.67, suggesting a potential upside of 133.80%. Given PolyPid's stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Sight Sciences beats PolyPid on 10 of the 15 factors compared between the two stocks.

How does PolyPid compare to TriSalus Life Sciences?

PolyPid (NASDAQ:PYPD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

PolyPid has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

26.5% of PolyPid shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PolyPid has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
TriSalus Life Sciences	$45.15M	5.48	-$39.23M	-$1.41	N/A

PolyPid has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

PolyPid presently has a consensus target price of $11.67, suggesting a potential upside of 133.80%. TriSalus Life Sciences has a consensus target price of $7.50, suggesting a potential upside of 86.10%. Given PolyPid's stronger consensus rating and higher possible upside, equities analysts clearly believe PolyPid is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, TriSalus Life Sciences had 3 more articles in the media than PolyPid. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 0 mentions for PolyPid. PolyPid's average media sentiment score of 0.00 equaled TriSalus Life Sciences'average media sentiment score.

Company	Overall Sentiment
PolyPid	Neutral
TriSalus Life Sciences	Neutral

Summary

PolyPid beats TriSalus Life Sciences on 9 of the 14 factors compared between the two stocks.

How does PolyPid compare to Treace Medical Concepts?

PolyPid (NASDAQ:PYPD) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

PolyPid has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Treace Medical Concepts	$207.32M	1.40	-$59M	-$0.97	N/A

In the previous week, Treace Medical Concepts had 3 more articles in the media than PolyPid. MarketBeat recorded 3 mentions for Treace Medical Concepts and 0 mentions for PolyPid. Treace Medical Concepts' average media sentiment score of 0.21 beat PolyPid's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Overall Sentiment
PolyPid	Neutral
Treace Medical Concepts	Neutral

PolyPid has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

PolyPid currently has a consensus price target of $11.67, suggesting a potential upside of 133.80%. Treace Medical Concepts has a consensus price target of $4.77, suggesting a potential upside of 6.24%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

PolyPid has a net margin of 0.00% compared to Treace Medical Concepts' net margin of -29.44%. Treace Medical Concepts' return on equity of -67.04% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

26.5% of PolyPid shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

PolyPid beats Treace Medical Concepts on 8 of the 15 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$97.90M	$2.96B	$6.44B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-2.61	18.43	24.67	23.99
Price / Sales	N/A	326.44	528.41	106.93
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	7.23	4.11	10.76	6.50
Net Income	-$34.17M	$64.45M	$3.56B	$336.88M
7 Day Performance	9.43%	1.41%	1.03%	-0.14%
1 Month Performance	-0.60%	1.04%	0.45%	0.77%
1 Year Performance	39.39%	23.88%	29.69%	28.49%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PYPD PolyPid	2.2477 of 5 stars	$4.99 -2.7%	$11.67 +133.8%	+35.6%	$97.90M	N/A	N/A	80
ELMD Electromed	1.2472 of 5 stars	$37.55 +0.3%	$37.50 -0.1%	+81.3%	$310.91M	$71.75M	50.07	160
CARL Carlsmed	N/A	$10.57 -4.2%	$19.33 +82.9%	N/A	$299.99M	$50.51M	N/A	100
SGHT Sight Sciences	2.7002 of 5 stars	$5.02 flat	$8.14 +62.2%	+24.7%	$273.14M	$77.36M	N/A	210
TLSI TriSalus Life Sciences	2.9239 of 5 stars	$4.16 -1.0%	$7.50 +80.3%	-23.8%	$257.95M	$45.15M	N/A	106

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors

PYPD vs. ELMD, CARL, SGHT, TLSI, and TMCI

How does PolyPid compare to Electromed?

Summary

How does PolyPid compare to Carlsmed?

Summary

How does PolyPid compare to Sight Sciences?

Summary

How does PolyPid compare to TriSalus Life Sciences?

Summary

How does PolyPid compare to Treace Medical Concepts?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PolyPid (PYPD) Competitors

PYPD vs. ELMD, CARL, SGHT, TLSI, and TMCI

How does PolyPid compare to Electromed?

Do analysts prefer PYPD or ELMD?

Does the media favor PYPD or ELMD?

Which has more volatility and risk, PYPD or ELMD?

Do insiders and institutionals hold more shares of PYPD or ELMD?

Is PYPD or ELMD more profitable?

Which has higher valuation and earnings, PYPD or ELMD?

Summary

How does PolyPid compare to Carlsmed?

Is PYPD or CARL more profitable?

Do analysts prefer PYPD or CARL?

Do institutionals & insiders hold more shares of PYPD or CARL?

Does the media prefer PYPD or CARL?

Which has preferable valuation & earnings, PYPD or CARL?

Summary

How does PolyPid compare to Sight Sciences?

Is SGHT or PYPD more profitable?

Which has better earnings & valuation, SGHT or PYPD?

Does the media prefer SGHT or PYPD?

Which has more volatility and risk, SGHT or PYPD?

Do analysts recommend SGHT or PYPD?

Do institutionals and insiders hold more shares of SGHT or PYPD?

Summary

How does PolyPid compare to TriSalus Life Sciences?

Is PYPD or TLSI more profitable?

Do institutionals & insiders hold more shares of PYPD or TLSI?

Which has stronger valuation & earnings, PYPD or TLSI?

Which has more volatility & risk, PYPD or TLSI?

Do analysts recommend PYPD or TLSI?

Does the media favor PYPD or TLSI?

Summary

How does PolyPid compare to Treace Medical Concepts?

Which has better earnings and valuation, PYPD or TMCI?

Does the media refer more to PYPD or TMCI?

Which has more risk and volatility, PYPD or TMCI?

Do analysts recommend PYPD or TMCI?

Is PYPD or TMCI more profitable?

Do insiders & institutionals hold more shares of PYPD or TMCI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools